Form 10-Q Viking Therapeutics, For: Sep 30

Go back to Form 10-Q Viking Therapeutics, For: Sep 30

BTIG Reiterates Buy Rating on Viking Therapeutic (VKTX)

October 24, 2024 5:42 AM EDT

BTIG analyst Justin Zelin reiterated a Buy rating and $125.00 price target on Viking Therapeutic (NASDAQ: VKTX).

The analyst comments "Viking reported 3Q24 earnings with focus on the higher dose oral VK2735 data expected at Obesity Week in a poster presentation... More